SensoLyte® 520 MMP-9 Assay Kit Fluorimetric - 1 kit
- Cat.Number : AS-71155
- Manufacturer Ref. :
-
Availability :
In stock
- Shipping conditions : Ice delivery fees must be applied
Alternative choices
MMP-9 (gelatinase-B, collagenase-IV) is involved in quite a few diseases such as a cancer, angiogenesis, alopecia and metastasis.
SensoLyte® 520 MMP-9 Assay Kit uses a 5-FAM (fluorophore) and QXL520™ (quencher) labeled FRET peptide substrates for continuous measurement of the enzyme activities. In an intact FRETpeptide, the fluorescence of 5-FAM is quenched by QXL520™. Upon the cleavage of the FRET peptide by MMP-9, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL520™ based FRET peptide is less interfered by the autofluorescence of test compounds and cellular components and provides better assay sensitivity.
Members of the MMP family have poor substrate sequence specificity, making it difficult to use a peptide substrate alone to differentiate the activity of a particular MMP from other MMPs. If several MMPs are coexisting in your samples and you would like to specifically measure MMP-9 activity, please choose the SensoLyte® Plus MMP-9 Assay Kit, Cat# AS-72017.
Specifications
Packaging | |
Kits components |
|
---|---|
Chemistry | |
UniProt number |
|
Properties | |
Absorbance (nm) |
|
Emission (nm) |
|
Storage & stability | |
Storage Conditions |
|
Activity | |
Application | |
Biomarker Target | |
Detection Method | |
Detection Limit |
|
Research Area | |
Sub-category Research Area | |
Usage |
|
Codes | |
Code Nacres |
|
Downloads
You may also be interested in the following product(s)
Citations
Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats
Cereb Cortex . 2011 Jun 17 ; 22(3) 725-34 | DOI : 10.1093/cercor/bhr158
- M. Spolidoro
- et al
Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts.
Am J Sports Med . 2014 Mar 13 ; 42 1211 | DOI : 10.1177/0363546514524710
- M.A. Pifer
- et al
Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis
J Hum Genet . 2012 Jan 12 ; 57 176 | DOI : 10.1038/jhg.2011.148
- H. Inoue
- et al
Urine matrix metalloproteinases (MMPs) as biomarkers for the progression of fracture healing.
Injury . 2012 Mar 01 ; 43 274 | DOI : 10.1016/j.injury.2011.05.038
- N.A. Wigner
- et al
Intracerebroventricular administration of an endothelin ETB-receptor agonist increases expression of matrix metalloproteinase-2 and -9 in rat brain
Neuroscience . 2007 Jun 06 ; 147 620 | DOI : 10.1016/j.neuroscience.2007.04.047
- Y. Koyama
- et al
A novel pharmacophore model for the design of anthrax lethal factor inhibitors
Chem Biol Drug Des . 2010 Jun 21 ; 76 263 | DOI : 10.1111/j.1747-0285.2010.01000.x
- H. Yuan
- et al
Rhodamine derivatives as selective protease inhibitors against bacterial toxins
Chem Biol Drug Des . 2008 Jan 19 ; 71 131 | DOI : 10.1111/j.1747-0285.2007.00617.x
- S.L. Johnson
- et al
Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein
Eur Respir J . 2008 Mar 05 ; 32 405 | DOI : 10.1183/09031936.00173207
- O. Soehnlein
- et al
A high-throughput screening approach to anthrax lethal factor inhibition
Bioorg Chem . 2007 Feb 22 ; 35 306 | DOI : 10.1016/j.bioorg.2006.12.005
- S.L. Johnson
- et al